Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Research Report 2024

Publication ID:

PB501253358

Publication Date:

January 6, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services was valued at US$ 445 million in the year 2023 and is projected to reach a revised size of US$ 866 million by 2030, growing at a CAGR of 9.8% during the forecast period.
Proteolysis Targeting Chimeras (PROTACs) are a series of hetero-bifunctional molecules that hijack the body鈥檚 own natural disposal system to initiate selective degradation of the protein of interest (POI). PROTACs have the potential to overcome most of the limitations of small molecule inhibitors, and they offer several advantages of the traditional concepts of drug discovery.
North American market for Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services in Targeted Protein Degradation is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services include WuXi AppTec, Syngene International Limited, Charles River Laboratories, Veranova, L.P., Aurigene Pharmaceutical Services Ltd, BOC Sciences, BPS Bioscience, Bio-Techne, Apeloa Pharmaceutical Co. Ltd., Aganitha AI Inc., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services.
The Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
WuXi AppTec
Syngene International Limited
Charles River Laboratories
Veranova, L.P.
Aurigene Pharmaceutical Services Ltd
BOC Sciences
BPS Bioscience
Bio-Techne
Apeloa Pharmaceutical Co. Ltd.
Aganitha AI Inc.
Creative Biolabs
Segment by Type
PROTACs Targeting Protein Kinases
PROTACs Targeting Nuclear Receptors
PROTACs Targeting BET Proteins
PROTACs Targeting Additional Protein
Segment by Application
Targeted Protein Degradation
Drug Discovery
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 PROTACs Targeting Protein Kinases
1.2.3 PROTACs Targeting Nuclear Receptors
1.2.4 PROTACs Targeting BET Proteins
1.2.5 PROTACs Targeting Additional Protein
1.3 麻豆原创 by Application
1.3.1 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Targeted Protein Degradation
1.3.3 Drug Discovery
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Perspective (2019-2030)
2.2 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Growth Trends by Region
2.2.1 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Dynamics
2.3.1 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Industry Trends
2.3.2 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Drivers
2.3.3 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Challenges
2.3.4 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Players by Revenue
3.1.1 Global Top Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Players by Revenue (2019-2024)
3.1.2 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Revenue
3.4 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Concentration Ratio
3.4.1 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Revenue in 2023
3.5 Global Key Players of Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Head office and Area Served
3.6 Global Key Players of Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services, Product and Application
3.7 Global Key Players of Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Breakdown Data by Type
4.1 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecasted 麻豆原创 Size by Type (2025-2030)
5 Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Breakdown Data by Application
5.1 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Size (2019-2030)
6.2 North America Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Size by Country (2019-2024)
6.4 North America Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Size (2019-2030)
7.2 Europe Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Size by Country (2019-2024)
7.4 Europe Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Size (2019-2030)
9.2 Latin America Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 WuXi AppTec
11.1.1 WuXi AppTec Company Details
11.1.2 WuXi AppTec Business Overview
11.1.3 WuXi AppTec Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Introduction
11.1.4 WuXi AppTec Revenue in Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Business (2019-2024)
11.1.5 WuXi AppTec Recent Development
11.2 Syngene International Limited
11.2.1 Syngene International Limited Company Details
11.2.2 Syngene International Limited Business Overview
11.2.3 Syngene International Limited Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Introduction
11.2.4 Syngene International Limited Revenue in Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Business (2019-2024)
11.2.5 Syngene International Limited Recent Development
11.3 Charles River Laboratories
11.3.1 Charles River Laboratories Company Details
11.3.2 Charles River Laboratories Business Overview
11.3.3 Charles River Laboratories Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Introduction
11.3.4 Charles River Laboratories Revenue in Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Business (2019-2024)
11.3.5 Charles River Laboratories Recent Development
11.4 Veranova, L.P.
11.4.1 Veranova, L.P. Company Details
11.4.2 Veranova, L.P. Business Overview
11.4.3 Veranova, L.P. Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Introduction
11.4.4 Veranova, L.P. Revenue in Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Business (2019-2024)
11.4.5 Veranova, L.P. Recent Development
11.5 Aurigene Pharmaceutical Services Ltd
11.5.1 Aurigene Pharmaceutical Services Ltd Company Details
11.5.2 Aurigene Pharmaceutical Services Ltd Business Overview
11.5.3 Aurigene Pharmaceutical Services Ltd Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Introduction
11.5.4 Aurigene Pharmaceutical Services Ltd Revenue in Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Business (2019-2024)
11.5.5 Aurigene Pharmaceutical Services Ltd Recent Development
11.6 BOC Sciences
11.6.1 BOC Sciences Company Details
11.6.2 BOC Sciences Business Overview
11.6.3 BOC Sciences Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Introduction
11.6.4 BOC Sciences Revenue in Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Business (2019-2024)
11.6.5 BOC Sciences Recent Development
11.7 BPS Bioscience
11.7.1 BPS Bioscience Company Details
11.7.2 BPS Bioscience Business Overview
11.7.3 BPS Bioscience Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Introduction
11.7.4 BPS Bioscience Revenue in Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Business (2019-2024)
11.7.5 BPS Bioscience Recent Development
11.8 Bio-Techne
11.8.1 Bio-Techne Company Details
11.8.2 Bio-Techne Business Overview
11.8.3 Bio-Techne Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Introduction
11.8.4 Bio-Techne Revenue in Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Business (2019-2024)
11.8.5 Bio-Techne Recent Development
11.9 Apeloa Pharmaceutical Co. Ltd.
11.9.1 Apeloa Pharmaceutical Co. Ltd. Company Details
11.9.2 Apeloa Pharmaceutical Co. Ltd. Business Overview
11.9.3 Apeloa Pharmaceutical Co. Ltd. Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Introduction
11.9.4 Apeloa Pharmaceutical Co. Ltd. Revenue in Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Business (2019-2024)
11.9.5 Apeloa Pharmaceutical Co. Ltd. Recent Development
11.10 Aganitha AI Inc.
11.10.1 Aganitha AI Inc. Company Details
11.10.2 Aganitha AI Inc. Business Overview
11.10.3 Aganitha AI Inc. Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Introduction
11.10.4 Aganitha AI Inc. Revenue in Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Business (2019-2024)
11.10.5 Aganitha AI Inc. Recent Development
11.11 Creative Biolabs
11.11.1 Creative Biolabs Company Details
11.11.2 Creative Biolabs Business Overview
11.11.3 Creative Biolabs Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Introduction
11.11.4 Creative Biolabs Revenue in Proteolysis Targeting Chimera (PROTAC) Development and Manufacturing Services Business (2019-2024)
11.11.5 Creative Biolabs Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

WuXi AppTec
Syngene International Limited
Charles River Laboratories
Veranova, L.P.
Aurigene Pharmaceutical Services Ltd
BOC Sciences
BPS Bioscience
Bio-Techne
Apeloa Pharmaceutical Co. Ltd.
Aganitha AI Inc.
Creative Biolabs

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.